# Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

> **NCT04498117** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CanariaBio Inc.** · enrollment: 615 (actual)

## Conditions studied

- Carcinoma, Ovarian Epithelial
- Ovarian Neoplasms
- Ovarian Cancer
- Ovarian Serous Adenocarcinoma
- Fallopian Tube Neoplasms
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Peritoneal Cancer
- Peritoneal Carcinoma
- Peritoneal Neoplasms

## Interventions

- **BIOLOGICAL:** Oregovomab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Placebo
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04498117
- **Lead sponsor:** CanariaBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-25
- **Primary completion:** 2026-12-26
- **Final completion:** 2028-08-26
- **Target enrollment:** 615 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498117, "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04498117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*